SCHEMBL24426171

SCHEMBL24426171

CC(=O)c1ccc(NC(=O)N2CCN(c3nc(Nc4ccc(N5CCOCC5)cc4)ncc3N)CC2)cc1

nearest known ligand 0.81

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 10/20 0.81
▸ FLT3 P36888 7/20 0.81
▸ MAPT P10636 4/20 0.54
▸ ALDH1A1 P00352 3/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ KDM4E B2RXH2 2/20 0.53
▸ POLB P06746 1/20 0.53
▸ LMNA P02545 1/20 0.53
▸ TP53 P04637 1/20 0.52
▸ THRB P10828 1/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ PANK3 Q9H999 1/20 0.52
▸ JAK3 P52333 1/20 0.51
▸ ATM Q13315 1/20 0.51
▸ PTGS2 P35354 1/20 0.51
▸ SYK P43405 1/20 0.47
▸ PIK3R1 P27986 1/20 0.47
▸ PIK3CA P42336 1/20 0.47
▸ MTOR P42345 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22860801 0.90 JAK2 (0.82) JAK2FLT3MAPTALDH1A1SMN1; SMN2
SCHEMBL28435361 0.88 JAK2 (0.63) JAK2FLT3MAPTALDH1A1SMN1; SMN2
SCHEMBL24426180 0.87 JAK2 (0.77) JAK2FLT3MAPTALDH1A1SMN1; SMN2
SCHEMBL28443644 0.86 JAK2 (0.76) JAK2FLT3MAPTALDH1A1SMN1; SMN2
SCHEMBL28442012 0.84 JAK2 (0.57) JAK2FLT3SYK
SCHEMBL24426212 0.83 JAK2 (1.00) JAK2FLT3MAPTALDH1A1SMN1; SMN2
SCHEMBL29236036 0.83 JAK2 (0.70) JAK2FLT3MAPTALDH1A1SMN1; SMN2
SCHEMBL29235901 0.82 JAK2 (0.85) JAK2FLT3MAPTALDH1A1SMN1; SMN2
SCHEMBL24426218 0.82 PIK3R1 (0.70) JAK2FLT3MAPTALDH1A1SMN1; SMN2
SCHEMBL28435360 0.81 JAK2 (0.56) JAK2FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220259196-A1 2-AMINOPYRIMIDINE COMPOUND AND USES THEREOF SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2022-08-18 — — US claimed
EP-3998254-A1 2-AMINOPYRIMIDINE COMPOUND AND APPLICATION THEREOF Shenyang Pharmaceutical University (CN) 2022-05-18 — — EP claimed
CN-113891881-A 2-aminopyrimidine compounds and application thereof 沈阳药科大学 2022-01-04 — — CN claimed
US-20220259196-A1 2-AMINOPYRIMIDINE COMPOUND AND USES THEREOF SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2022-08-18 — — US disclosed
EP-3998254-A1 2-AMINOPYRIMIDINE COMPOUND AND APPLICATION THEREOF Shenyang Pharmaceutical University (CN) 2022-05-18 — — EP disclosed
EP-3998254-A1 2-AMINOPYRIMIDINE COMPOUND AND APPLICATION THEREOF Shenyang Pharmaceutical University (CN) 2022-05-18 — — EP disclosed
CN-113891881-A 2-aminopyrimidine compounds and application thereof 沈阳药科大学 2022-01-04 — — CN disclosed
CN-111423384-B 2-aminopyrimidine compounds and application thereof 沈阳药科大学 2021-10-15 — — CN disclosed
CN-111423384-A 2-aminopyrimidine compounds and application thereof 沈阳药科大学 2020-07-17 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220259196-A1 2-AMINOPYRIMIDINE COMPOUND AND USES THEREOF DPYD, TPMT, TYMP JAK2 23/4885FLT3 35/4885MAPT 4018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback